Cartesian Therapeutics Inc (RNAC)

Feb 18, 2025

Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq

Feb 18, 2025

Feb 18, 2025

Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 18, 2025

Feb 18, 2025

Major mRNA Cell Therapy Player Sets Ambitious 3-Conference Roadshow: Key Dates Inside - StockTitan

Feb 18, 2025

Feb 15, 2025

Mirae Asset Global Investments Co. Ltd. Has $82,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Feb 15, 2025

Feb 14, 2025

What is Leerink Partnrs' Estimate for RNAC FY2024 Earnings? - MarketBeat

Feb 14, 2025

Feb 13, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - MarketBeat

Feb 13, 2025

Feb 12, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Analysts - Defense World

Feb 12, 2025

Feb 11, 2025

Leerink Partnrs Issues Optimistic Estimate for RNAC Earnings - Defense World

Feb 11, 2025

Feb 09, 2025

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025

Feb 07, 2025

What is Leerink Partnrs’ Forecast for RNAC FY2029 Earnings? - Armenian Reporter

Feb 07, 2025

Feb 06, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Feb 06, 2025

Feb 06, 2025

Cartesian Therapeutics Issues Strategic Employee Stock Options Worth $3.3MInside Details - StockTitan

Feb 06, 2025

Jan 31, 2025

Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - MarketBeat

Jan 31, 2025

Jan 28, 2025

Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC - Defense World

Jan 28, 2025

Jan 28, 2025

Cartesian Therapeutics Announces FDA Special Protocol - GlobeNewswire

Jan 28, 2025

Jan 27, 2025

Cartesian Therapeutics Secures FDA SPA Agreement For Phase 3 AURORA Trial - Nasdaq

Jan 27, 2025

Jan 27, 2025

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat

Jan 27, 2025

Jan 27, 2025

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - The Manila Times

Jan 27, 2025

Jan 27, 2025

Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis - Marketscreener.com

Jan 27, 2025

Jan 27, 2025

FDA Grants Special Protocol Assessment for Cartesian's Myasthenia Gravis Treatment - StockTitan

Jan 27, 2025

Jan 22, 2025

Barclays PLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 22, 2025

Jan 18, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World

Jan 18, 2025

Jan 17, 2025

Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha

Jan 17, 2025

Jan 15, 2025

Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria

Jan 15, 2025

Jan 15, 2025

Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India

Jan 15, 2025

Jan 15, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat

Jan 15, 2025

Jan 14, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jan 14, 2025

Jan 13, 2025

Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Jan 13, 2025

Jan 13, 2025

Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks

Jan 13, 2025

Jan 13, 2025

Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire

Jan 13, 2025

Jan 13, 2025

Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan

Jan 13, 2025

Jan 08, 2025

Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail

Jan 08, 2025

Jan 08, 2025

Myasthenia Gravis Market Poised for Significant Growth from - openPR

Jan 08, 2025

Jan 08, 2025

Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia

Jan 08, 2025

Jan 08, 2025

Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 08, 2025

Jan 08, 2025

Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria

Jan 08, 2025

Jan 08, 2025

Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa

Jan 08, 2025

Jan 08, 2025

Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa

Jan 08, 2025

Jan 08, 2025

Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada

Jan 08, 2025

Jan 07, 2025

Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com

Jan 07, 2025

Jan 07, 2025

Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com

Jan 07, 2025